PainChek® Infant for Professionals is the world’s first validated medical device for automated assessment of post-procedural pain in infants aged 1-12 months.

PainChek® Infant for Professionals is an easy-to-use, secure smartphone-based medical device that uses artificial intelligence and facial analysis technology to assess and score pain levels in infants.

PainChek® meets regulatory standards for use in Australia, New Zealand, Canada, Singapore, Malaysia, the United Kingdom, and the European Union.


Target user sectors

  • Clinical trials
  • Children’s hospitals
  • Post surgical units
  • Healthcare professionals
  • General practitioners
  • Nurses

Intended use

If pain is suspected following a procedure such as immunisation or surgery, PainChek® Infant can be used to quickly and accurately quantify and monitor pain levels in infants aged under one. The tool is appropriate for use by GPs, nurses, and other medical professionals.

PainChek® Infant clinical research

In 2021, a PainChek® Infant clinical study, ‘Assessing procedural pain in infants: a feasibility study evaluating a point-of-care mobile solution based on automated facial analysis’1, was published in Lancet Digital Health, the world’s foremost health publication.

  • PainChek® Infant’s validity and reliability were assessed against the paper-based Neonatal Facial Coding System (NFCS-R), and the observer administered Visual Analogue Scale (VAS).
  • The study used video recordings of 40 infants aged 2-7 months of age, with more than 4,300 pain assessments completed in two separate evaluation sessions, four weeks apart.
  • PainChek® Infant pain scores demonstrated excellent correlation with NFCS-R and ObVAS scores, moderate to excellent inter-rater reliability and high levels of internal consistency.
  • The findings provide evidence that PainChek® Infant offers a valid and reliable means of assessing and monitoring procedural pain in infants.

A 2023 Journal of Medical Internet Research study, ‘The Clinical Suitability of an Artificial Intelligence-Enabled Pain Assessment Tool for Use in Infants: Feasibility and Usability Evaluation Study’2 further demonstrates the clinical value of PainChek® Infant.

Researchers evaluated the accuracy and feasibility of PainChek® Infant against the internationally recognised COSMIN Guidelines.

The research showed that a PainChek® Infant score of 2 or above was highly predictive of the presence of pain.

Further, PainChek® Infant performed well across feasibility aspects, including interpretability (cutoff score defined), ease of administration, completion time (3 seconds), and clinician comprehensibility.

The Lancet

How it works

PainChek® Infant uses automated facial evaluation and analysis to detect six facial action units (AUs) indicative of the presence of pain:

  1. AU4 – Brow lowering
  2. AU9 – Wrinkling nose
  3. AU15 – Lip corner depression
  4. AU20 – Mouth stretch
  5. AU25 – Parting lips
  6. AU43 – Closed eyes

These indicators have been shown to be a prominent feature of pain-related distress in infants undergoing immunisation across a range of ages1.

The PainChek® Infant for Professionals app uses the camera of the mobile device to complete a 3-second scan of the child’s face to determine the presence of the above six AUs and provide a pain score.


Sources:

1 Hoti K, Chivers PT, Hughes JD. Assessing procedural pain in infants: a feasibility study evaluating a point-of-care mobile solution based on automated facial analysis. The Lancet Digital Health. 2021;3(10):e623-e634. doi:https://doi.org/10.1016/s2589-7500(21)00129-1
2Hughes JD, Chivers P, Hoti K. The Clinical Suitability of an Artificial Intelligence–Enabled Pain Assessment Tool for Use in Infants: Feasibility and Usability Evaluation Study. Journal of Medical Internet Research. 2023;25:e41992. doi:https://doi.org/10.2196/41992

If you are interested in learning more about PainChek® Infant for Professionals, contact us.